Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 13/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59720 | 0.86 | ACVRL1 (0.42) | ACVRL1MAP4K4KITRIPK1TNIK | |
| SCHEMBL24236922 | 0.84 | MAP4K4 (0.42) | ACVRL1MAP4K4PIK3CAKITRIPK1 | |
| SCHEMBL59361 | 0.83 | ACVRL1 (0.52) | ACVRL1MAP4K4KITRIPK1TNIK | |
| SCHEMBL5077202 | 0.82 | ACVRL1 (0.53) | ACVRL1MAP4K4KITRIPK1TNIK | |
| SCHEMBL65554 | 0.82 | MAP4K4 (0.41) | ACVRL1MAP4K4RIPK1TNIK | |
| SCHEMBL23885102 | 0.80 | RIPK1 (0.38) | ACVRL1MAP4K4RIPK1TNIK | |
| SCHEMBL14488045 | 0.79 | ACVRL1 (0.48) | ACVRL1MAP4K4RIPK1TNIK | |
| SCHEMBL24312569 | 0.78 | MAP4K4 (0.38) | ACVRL1MAP4K4PIK3CARIPK1TNIK | |
| SCHEMBL25008853 | 0.78 | RIPK1 (0.33) | ACVRL1MAP4K4PIK3CARIPK1 | |
| SCHEMBL24982191 | 0.78 | ADORA2A (0.35) | ACVRL1MAP4K4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9090621-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | ACVRL1 4575/4885MAP4K4 55/4885PIK3CA 186/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ACVRL1 941/4885MAP4K4 147/4885PIK3CA 207/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885MAP4K4 151/4885PIK3CA 245/4885 |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | ACVRL1 4575/4885MAP4K4 55/4885PIK3CA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.